Thu, Sep 18, 2014, 4:32 AM EDT - U.S. Markets open in 4 hrs 58 mins

Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

kevinvests 59 posts  |  Last Activity: Sep 9, 2014 7:52 PM Member since: Jul 11, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    NEW HOLDER OF MNKD-----very interesting:

    by mikesmilitaria Sep 9, 2014 6:07 PM
    kevinvests kevinvests Sep 9, 2014 7:52 PM Flag

    Now we are talking, the goliaths are buying. Once they have enough they will manipulate the pps up. With 77 mil shares shorted, it will be a very easy manipulation. Adam Feurstein and Toubillion will not standup to the Goliaths of BofA and Vanguard.

  • kevinvests kevinvests Sep 9, 2014 3:45 PM Flag

    it's called accumulation and then manippulation. Gotta give them enough time to collect cheap shares first. Then they will bring it up.

  • kevinvests kevinvests Sep 3, 2014 12:57 PM Flag

    500 sh, at 350 est

  • kevinvests kevinvests Sep 3, 2014 12:33 PM Flag

    please put down how many shares are you going to buy and put down the time.

  • Reply to

    Why doesn't mnkd sell rights to technosphere?

    by kevinvests Aug 22, 2014 12:10 PM
    kevinvests kevinvests Aug 22, 2014 2:25 PM Flag

    mnkd use the same dosing tactic with Afrezza, and insulin is a drug that has very narrow safety margin. For example, each breath gives max 10 units but variability may range somewhere around 2-10 units. Thus, someone who needs 8 units to be therapeeutic may only get 2 units. That's the reason why they couldn't get HbA1c lower than SubQ insulin, even though by theory Afrezza should lower HbA1c

  • Reply to

    Why doesn't mnkd sell rights to technosphere?

    by kevinvests Aug 22, 2014 12:10 PM
    kevinvests kevinvests Aug 22, 2014 1:54 PM Flag

    BTW, alot of other drugs have wider safety margins than insulin, meaning that there is a wide range of dosing and it is still safe. Let's use motrim, since almost everyone is familiar with it and it's kidney toxic effect renders inhalation a big advantage in that the dose can be significantly reduced and still have quicker and similar pain control to oral form. In other words, pts with kidney problems can take inhalation motrim because the dose to relieve pain is smaller and action is quicker, yet still giving similar or even better pain relief.
    That is just one example, there are many applications and you can find special uses for inhalation forms. Drugs that have wider safety margin should fly by the FDA, all they have to show is safety profiles and efficacy which shoud be quick and easy.

  • Reply to

    Who's the manufacturer of Dreamboat inhaler?

    by kevinvests Aug 22, 2014 11:23 AM
    kevinvests kevinvests Aug 22, 2014 1:42 PM Flag

    most other drugs have wider safety margins than insulin-- all they have to show is safety profiles and efficacy which should be determined within a few years of studies, not going to be 10 years like Afrezza.

    For instance, you can inhale motrim for quicker response to pain and allows smaller dose and less impact on someone with kidney problems. Let's say, max dose that anyone can get from ONE puff is 200 mg but variability is between 20-200 mg each breath depending on patient's breaths. Drugs with wide saftey margins will sale like pancakes, no problem with FDA

  • Reply to

    Who's the manufacturer of Dreamboat inhaler?

    by kevinvests Aug 22, 2014 11:23 AM
    kevinvests kevinvests Aug 22, 2014 12:41 PM Flag

    true on that, but now that the platform is approved, it makes it easier and faster.

  • Reply to

    Why doesn't mnkd sell rights to technosphere?

    by kevinvests Aug 22, 2014 12:10 PM
    kevinvests kevinvests Aug 22, 2014 12:39 PM Flag

    LOL. you are correct, seems like a cash cow but behaves like a beggar.

  • there are hundreds, if not thousands, of drugs out in the market that have detrimental effect on the kidneys and liver from first pass metabolism. Hence patients with liver or kidney problems can not tolerate these drugs. Turn them into inhalations and bypass the liver. Inhaltion also allows smaller dose usage; therefore less toxic effect on the body and less impact on the ki.dneys metabolism which would benefit those with kidney problems greatly.

    Mnkd is sitting on a delivery platform that has been approved by the FDA; greenfield work isn't done folks. Sanofi is just the beginning.

  • Reply to

    Who's the manufacturer of Dreamboat inhaler?

    by kevinvests Aug 22, 2014 11:23 AM
    kevinvests kevinvests Aug 22, 2014 12:02 PM Flag

    true, but part of that deal, they may also want to have access to technosphere. I just can't believe that a delivery powder that has been accepted already by FDA will not undergo other drugs platform for inhalation. Think about it, why would you sit with technosphere when there are hundreds of other applications. Mnkd can sell rights to other companies to use technosphere.

    I am thinking Medtronic may ink a deal because they manufacture a lot of medical devices. Pfizer has alot of drugs that may be converted to inhalation for quicker response, or any drug that has detrimental impact on kidneys or liver can bypass these metabolic pathways where inhalation is more tolerable to the patients.

  • Amph for insulin
    Sanofi for comercial and sales
    The candidate to manufacture Dreamboat may also ink a deal for technosphere (Can't believe Greenfield was hired to just ink a simple deal with Sanofi; there has to be multiple deals).
    Short days are numbered....that is all i can say at this point.

  • Reply to

    SA article confirmed my suspicion

    by scappy25 Aug 13, 2014 6:06 PM
    kevinvests kevinvests Aug 13, 2014 7:37 PM Flag

    What?! you gotta be kiddin! that's $2.5 bil upfront pay. This may support my suspicion by management has been downplaying their success; there is always something not disclosed in these contracts.

  • kevinvests kevinvests Aug 13, 2014 12:16 PM Flag

    I was actually thinking that Sanofi, depending on how Afreeza is perceived by the market during the first half of 2015, may offer Mankind a complete buyout by 2015. But your insight is much brighter.

  • Reply to

    The $10 Billion missing insulin sinks bigtime

    by mannkindly Aug 12, 2014 9:06 PM
    kevinvests kevinvests Aug 12, 2014 10:13 PM Flag

    I am repeating myself again, insiders intentional put effort to lower share price.
    1) the 6 weeks silence after FDA approval
    2) Only after such long silence they came up with $150 mil up front payment that seemed like they are givin away Afrezza for free.
    3) You insulin storage comment where management could have easily said, "not FDA approved or certified but we are looking to get some certified and used in the future". But instead, he said, "could be bad, defective because it's so old"

    When management should have pumped but they didn't and they put so many negative spins on their own company; it has to be intentional. The question is why?

  • kevinvests kevinvests Aug 12, 2014 8:09 PM Flag

    That is my theory too. Buyout! I actually thought that management wasn't going to announce anything at the earnings conference. I predicted a speech that would go something like, " we are actively looking for partner and buyer, and we just need some more time to finalize our decison", and the stock would plumet ted, maybe more so than today. But that would have created a mob of angry investors and legal issue when they promised to have made their decision by 6 -8 weeks after FDA approval. Annoucing a partnership with Sanofi is more of a disguised. Thus Sanofi could buy everything, both technosphere and Afrezza. Or they could sell technosphere to a different company (less likely because Sanofi would still have to use technosphere.)

    A. Mann sold all his prior projects, at 89 yo, I am shocked that he took on this partnership.

  • kevinvests kevinvests Aug 12, 2014 7:54 PM Flag

    true but at the same time, everyone wants to protect their own pockets. Protect now is better protection in the future. If you read by first thread on this message, you would realize that we could be trading at above $20 at this moment, if management had done something like I suggested. Deceptive but still within legal rights.

    My point is: when it looked that bad, it had to be intentional

  • kevinvests kevinvests Aug 12, 2014 7:32 PM Flag

    that is the strange thing, Al Mann owned nearly all of that 47% insider shares. Why did he and along with his insiders who owned millions of shares hid in silence and watched their shares get destroyed after the biggest success in the company's history. To top it off, when they finally made their first announcement since FDA approval, the Sanofi initial pay was so low it almost seemed like they were giving away Afrezza for free. Clearly this was a setup because to be this bad you would have to put some effort into it. I have a theory but I want to hear what everyone else is thinking

  • It would only be logical for management to pump the stock after such an event, especially when they owned 47% of the shares. As long as you stay within the legal limits, you can lie and pump. If I was Al Mann I can call up my friend the Ceo of Merck, for example, and agree to a Merck buyout at let's say $8 bil. But I would also say, the decision wasn't finalized yet, it's still within legal limits to lie as long as I am ambiguous enough. The shares would have gotten pumped to $20/sh; shorts would have been torched mometarily. Then all of the sudden, I would say mnkd is more interested in a partner rather than a buyout and sign partner with Sanofi instead. At this point, investors would have been left with the impression that mnkd just turned down an $8 billion cash for bigger pay. Thye stock would probably rally even higher. than $20.

    So instead, management staid silent, allowed shorts to rape the share price for 6 weeks. When it came to Sanofi deal, eventhough the deal is for $925 mils paid in installments but the initial pay was only $150 mil that it got investors spooked, and the shorts jumped on and raped the share price again. IT JUST DOESN'T MAKE SENSE. It seemed like management intentionally wants the share price down for whatever reason. That is the puzzle that I can't figure out. #$%$ is going on?

  • By the time the drug is out, pts will be asking for it.

MNKD
6.23+0.04(+0.65%)Sep 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.